Edging closer towards the goal of a dengue vaccine
Dengue is a growing global problem that urgently needs to be addressed [1]. Similarly to yellow fever, dengue is caused by viruses of the flaviviridae family and transmitted by Aedes mosquitoes, but unlike yellow fever for which we have had a vaccine for more than 80 years, the first dengue vaccine...
| Päätekijät: | , |
|---|---|
| Muut tekijät: | |
| Aineistotyyppi: | Journal Article |
| Kieli: | English |
| Julkaistu: |
2016
|
| Aiheet: | |
| Linkit: | https://hdl.handle.net/10356/80193 http://hdl.handle.net/10220/40434 |
| _version_ | 1826115733073952768 |
|---|---|
| author | Wilder-Smith, Annelies Yoon, In-Kyu |
| author2 | Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet | Lee Kong Chian School of Medicine (LKCMedicine) Wilder-Smith, Annelies Yoon, In-Kyu |
| author_sort | Wilder-Smith, Annelies |
| collection | NTU |
| description | Dengue is a growing global problem that urgently needs to be addressed [1]. Similarly to yellow fever, dengue is caused by viruses of the flaviviridae family and transmitted by Aedes mosquitoes, but unlike yellow fever for which we have had a vaccine for more than 80 years, the first dengue vaccine is only available now. Research and Development funding for dengue vaccine development has more than tripled in the past decades, much of which is driven by vaccine manufacturers [2]. We have a robust pipeline with several promising dengue vaccine candidates, all using different approaches [3]. The only vaccine to have completed Phase 3 trials is the CYD-TDV (a live attenuated recombinant chimeric tetravalent dengue vaccine developed by Sanofi Pasteur) sponsored by Sanofi Pasteur. Interestingly, the relatedness to other flaviviruses played a role in the development of CYD-TDV in which the 17D yellow fever virus backbone is used for chimerization with dengue viruses (DENVs). CYD-TDV is a formulation of four chimeras, each one engineered to express the envelope and pre-membrane proteins from one of the four serotypes of DENV [4]. Dengvaxia (CYD-TDV) was first licensed in Mexico in December 2015, and is meanwhile licensed in three other countries. |
| first_indexed | 2024-10-01T03:59:59Z |
| format | Journal Article |
| id | ntu-10356/80193 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T03:59:59Z |
| publishDate | 2016 |
| record_format | dspace |
| spelling | ntu-10356/801932020-11-01T05:16:02Z Edging closer towards the goal of a dengue vaccine Wilder-Smith, Annelies Yoon, In-Kyu Lee Kong Chian School of Medicine (LKCMedicine) Efficacy Non-structural proteins Risk-benefit ratio Dengue vaccines CYD-TDV Dengue is a growing global problem that urgently needs to be addressed [1]. Similarly to yellow fever, dengue is caused by viruses of the flaviviridae family and transmitted by Aedes mosquitoes, but unlike yellow fever for which we have had a vaccine for more than 80 years, the first dengue vaccine is only available now. Research and Development funding for dengue vaccine development has more than tripled in the past decades, much of which is driven by vaccine manufacturers [2]. We have a robust pipeline with several promising dengue vaccine candidates, all using different approaches [3]. The only vaccine to have completed Phase 3 trials is the CYD-TDV (a live attenuated recombinant chimeric tetravalent dengue vaccine developed by Sanofi Pasteur) sponsored by Sanofi Pasteur. Interestingly, the relatedness to other flaviviruses played a role in the development of CYD-TDV in which the 17D yellow fever virus backbone is used for chimerization with dengue viruses (DENVs). CYD-TDV is a formulation of four chimeras, each one engineered to express the envelope and pre-membrane proteins from one of the four serotypes of DENV [4]. Dengvaxia (CYD-TDV) was first licensed in Mexico in December 2015, and is meanwhile licensed in three other countries. Accepted version 2016-04-15T06:06:08Z 2019-12-06T13:42:39Z 2016-04-15T06:06:08Z 2019-12-06T13:42:39Z 2016 Journal Article Wilder-Smith, A., & Yoon, I.-K. (2016). Edging closer towards the goal of a dengue vaccine. Expert Review of Vaccines, 15(4), 433-435. 1476-0584 https://hdl.handle.net/10356/80193 http://hdl.handle.net/10220/40434 10.1586/14760584.2016.1154459 en Expert Review of Vaccines © 2016 Taylor & Francis. This is the author created version of a work that has been peer reviewed and accepted for publication by Expert Review of Vaccines, Taylor & Francis. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1586/14760584.2016.1154459]. 8 p. application/pdf |
| spellingShingle | Efficacy Non-structural proteins Risk-benefit ratio Dengue vaccines CYD-TDV Wilder-Smith, Annelies Yoon, In-Kyu Edging closer towards the goal of a dengue vaccine |
| title | Edging closer towards the goal of a dengue vaccine |
| title_full | Edging closer towards the goal of a dengue vaccine |
| title_fullStr | Edging closer towards the goal of a dengue vaccine |
| title_full_unstemmed | Edging closer towards the goal of a dengue vaccine |
| title_short | Edging closer towards the goal of a dengue vaccine |
| title_sort | edging closer towards the goal of a dengue vaccine |
| topic | Efficacy Non-structural proteins Risk-benefit ratio Dengue vaccines CYD-TDV |
| url | https://hdl.handle.net/10356/80193 http://hdl.handle.net/10220/40434 |
| work_keys_str_mv | AT wildersmithannelies edgingclosertowardsthegoalofadenguevaccine AT yooninkyu edgingclosertowardsthegoalofadenguevaccine |